Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adolor Faces R&D Setbacks, One With Entereg

This article was originally published in The Pink Sheet Daily

Executive Summary

Adolor discontinues development of alvimopan to treat chronic opioid bowel dysfunction after unsuccessful partnering discussions; it will proceed with the preclinical compound ADL7445.

You may also be interested in...



Nektar Starts Major Push In Opioid-Induced Constipation Space

Biotechs that manage solid proof of concept in the challenging but potentially high-value area of opioid-induced constipation might find a receptive partnering audience in a variety of pharma quarters

Nektar Starts Major Push In Opioid-Induced Constipation Space

Biotechs that manage solid proof of concept in the challenging but potentially high-value area of opioid-induced constipation might find a receptive partnering audience in a variety of pharma quarters

Niche, Lackluster: Two Words That Sum Up 2008 NME Launches

The year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior

Related Content

Topics

UsernamePublicRestriction

Register

PS067139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel